Autopsy report · NCT03095287

Alphanate in Immune Tolerance Induction Therapy

“Terminated due to limited enrollment (non-safety related decision)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 8 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Grifols Therapeutics LLC

Sponsor type

Industry

Conditions

Hemophilia A, Congenital

Interventions

Alphanate

Participants

2

Sites

20

Countries

Canada, India, Italy, Russia, Spain, United States

Trials that died the same way

• Polycystic Liver Disease in Kidney Transplant
  “Terminated due to inadequate enrollment” (87% match in meaning)
• Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
  “Terminated due to lack of enrollment” (86% match in meaning)
• Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
  “terminated due to poor enrollment” (85% match in meaning)
• An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy
  “Terminated due to enrollment challenges” (83% match in meaning)
• Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
  “Terminated due to low enrollment.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.